STOCKHOLM, October 18, 2018 /PRNewswire/ --
Medicover has signed an agreement to acquire the Ukrainian
laboratory operations of Invitro. The operations consist of a total
of 61 blood drawing points (BDP's) and one laboratory, focused on
eastern and central Ukraine. The
business is expected to be consolidated in the beginning of 2019.
The transaction is subject to customary regulatory approvals.
End of September 2018, Medicover
had a total of 229 BDP's in Ukraine and will through the acquisition
increase distribution reach in Ukraine. Synergies will be achieved through
combining the laboratory facilities and other support functions.
The purchase price amount to EUR 6
million, implying a low single digit EBITDA multiple after
full impact of synergies.
"The acquisition of Invitro's Ukrainian operations extends our
geographical coverage for customers and also shows our long-term
commitment to providing the Ukrainian population with health
services. We will improve access to our wide offering of quality
diagnostic tests following the acquisition", says Fredrik Rågmark,
CEO Medicover.
Medicover is a leading international healthcare and diagnostic
services company and was founded in 1995. Medicover operates a
large number of ambulatory clinics, hospitals, specialty-care
facilities and laboratories and the largest markets are
Poland and Germany. In 2017, Medicover had revenues
around €580 million and 15,900 employees. For more information, go
to http://www.medicover.com
PDF: http://mb.cision.com/Main/15662/2647547/928311.pdf
SOURCE Medicover
